MARKET

CALC

CALC

CALCIMEDICA INC
NASDAQ
0.5651
+0.0251
+4.65%
Opening 10:08 04/01 EDT
OPEN
0.5588
PREV CLOSE
0.5400
HIGH
0.5965
LOW
0.5419
VOLUME
49.83K
TURNOVER
--
52 WEEK HIGH
7.20
52 WEEK LOW
0.4606
MARKET CAP
8.90M
P/E (TTM)
-0.2870
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CALC last week (0323-0327)?
Weekly Report · 2d ago
Weekly Report: what happened at CALC last week (0316-0320)?
Weekly Report · 03/23 09:51
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 03/20 21:05
CalciMedica Receives Nasdaq Deficiency Notices on Listing Standards
TipRanks · 03/18 21:04
CalciMedica flags Nasdaq noncompliance as market value falls below USD 35 million
Reuters · 03/18 20:33
Weekly Report: what happened at CALC last week (0309-0313)?
Weekly Report · 03/16 09:51
Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), CalciMedica (CALC)
TipRanks · 03/09 14:41
Weekly Report: what happened at CALC last week (0302-0306)?
Weekly Report · 03/09 09:52
More
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Webull offers Calcimedica Inc stock information, including NASDAQ: CALC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CALC stock methods without spending real money on the virtual paper trading platform.